ZyVersa Therapeutics Reports $2.2 Million Net Loss in Q2 2025, Seeks Additional Financing

ZyVersa Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $2.2 million for the three months ended June 30, 2025, a decrease from a net loss of $2.8 million during the same period in 2024. For the six months ended June 30, 2025, the company incurred a net loss of approximately $4.5 million, compared to $5.6 million for the first half of 2024. The reduction in losses is attributed to a decrease in operating expenses, which totaled $2.0 million for the second quarter of 2025, down from $2.8 million in the prior year. Research and development expenses decreased by 42.2% to $410,000, while general and administrative expenses fell by 20.1% to $1.6 million.

The company's total assets as of June 30, 2025, were approximately $19.6 million, a decline from $20.6 million at the end of 2024. Current assets decreased significantly, primarily due to a reduction in cash, which fell to $72,086 from $1.5 million at the end of the previous fiscal year. ZyVersa's current liabilities increased to $12.7 million, up from $11.2 million, leading to a working capital deficit of approximately $12.1 million. The accumulated deficit reached $117.1 million as of June 30, 2025.

In terms of strategic developments, ZyVersa has not generated any revenue to date and continues to focus on the development of its product candidates, including VAR 200 and IC 100, aimed at treating chronic renal and inflammatory diseases. The company has been actively seeking additional financing to support its operations, as it expects to incur significant expenses related to ongoing research and development activities. ZyVersa entered into an Equity Purchase Agreement in June 2025, allowing it to sell up to $10 million in common stock to Williamsburg Venture Holdings, LLC, which may provide necessary capital for its initiatives.

Operationally, ZyVersa's employee headcount remains stable, with no significant changes reported. The company continues to rely on a vendor for critical research and development activities, which accounted for 56% of its accounts payable as of June 30, 2025. The company has also faced challenges, including a recent determination from Nasdaq to deny its request to continue listing on the Nasdaq Capital Market, resulting in its common stock being traded on the OTCQB Venture Market starting July 28, 2025.

Looking ahead, ZyVersa anticipates continued operating losses as it progresses with its clinical trials and seeks regulatory approvals for its product candidates. The company emphasizes the need for additional financing to sustain its operations and achieve profitability, which remains uncertain. ZyVersa's management is actively evaluating various financing opportunities, including public and private equity or debt financing, to support its ongoing development efforts.